Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 1 January 2007, Vol. 109, No. 1, pp. 71-77.
Prepublished online as a Blood First Edition Paper on September 5, 2006; DOI 10.1182/blood-2006-03-007146.


This Article
Right arrow Full Text (PDF)
Right arrow Supplemental Figures
Right arrow All Versions of this Article:
blood-2006-03-007146v1
109/1/71    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Delhommeau, F.
Right arrow Articles by Giraudier, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Delhommeau, F.
Right arrow Articles by Giraudier, S.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Next Article next article arrow

Submitted March 3, 2006
Accepted August 16, 2006

Evidence that the JAK2 G1849T (V617F) mutation occurs in a lympho-myeloid progenitor in polycythemia vera and idiopathic myelofibrosis

Francois Delhommeau, Sabrina Dupont, Carole Tonetti, Aline Masse, Isabelle Godin, Jean Pierre Le Couedic, Najet Debili, Patrick Saulnier, Nicole Casadevall, William Vainchenker, and Stephane Giraudier*

INSERM U790; Universite Paris XI; Institut Gustave Roussy, Villejuif, France
Laboratoire d'Hematologie, Hopital H. Mondor, Assistance Publique-Hopitaux de Paris, Creteil, France
Laboratoire de Recherche Translationnelle, Institut Gustave Roussy, Villejuif, France
Laboratoire d'Hematologie, Hopital Hotel-Dieu, Assistance Publique-Hopitaux de Paris, Paris, France

* Corresponding author; email: stephane.giraudier{at}hmn.ap-hop-paris.fr.

The JAK2 V617F mutation has recently been described as an essential oncogenic event associated with Polycythemia Vera (PV), Idiopathic Myelofibrosis (IMF) and Essential Thrombocythemia. This mutation has been detected in all myeloid lineages but has not yet been detected in lymphoid cells. This raises the question whether this molecular event occurs in a true lymphoid/myeloid progenitor cell. In this work, we studied the presence of the mutation in peripheral blood cells and sorted B, T, and NK cells from PV and IMF. We detected the JAK2 V617F mutation in B and NK cells in approximately half IMF patients and a minority of PV patients. Moreover, in few cases patients with IMF had mutated peripheral T cells. The mutation (homozygous or heterozygous) could be subsequently detected in B/NK/Myeloid progenitors from PV and IMF, with a much higher frequency in clones derived from IMF. Using the FTOC assay, the mutation was also detected in all T cell fractions derived from IMF and PV CD34+ cells. These results demonstrate that myeloproliferative disorders take their origin in a true myeloid/lymphoid progenitor cell but that their phenotype is related to a downstream selective proliferative advantage of the myeloid lineages.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020